\u00a0<\/p>\n
(EMAILWIRE.COM<\/a>, September 12, 2024 ) CBD API Market<\/a> to Record an Exponential CAGR by 2031 – Exclusive Report by InsightAce Analytic<\/p>\n \u0093CBD API Market\u0094 is estimated to grow with a CAGR of 42.79% from 2024 to 2031, according to a new report by InsightAce Analytic. <\/p>\n Get Free Access to Demo Report, Excel Pivot and ToC : https:\/\/www.insightaceanalytic.com\/request-sample\/1478<\/a><\/p>\n Latest Drivers Restraint and Opportunities Market Snapshot:<\/p>\n Key factors influencing the global CBD API market are: The following are the primary obstacles to the CBD API market’s expansion: Future expansion opportunities for the global CBD API market include: Expert Knowledge, Just a Click Away:https:\/\/calendly.com\/insightaceanalytic\/30min?month=2024-02<\/a><\/p>\n Market Analysis:<\/p>\n Increasing awareness and interest in Cannabidiol has propelled the growth CBD API market. The demand for natural medicines like Cannabidiol (CBD) has increased as a consequence of the positive experiences of influencers and locals using CBD. Furthermore, many consumers are looking for natural alternatives to conventional Pharmaceutical products. This shift is driven by a desire for products that are perceived as safer and sustainable, and aligned with a holistic approach to health and wellness. <\/p>\n List of Prominent Players in the CBD API Market: Unlock Your GTM Strategy: https:\/\/www.insightaceanalytic.com\/customisation\/1478<\/a><\/p>\n Recent Developments: CBD API Market Dynamics:<\/p>\n Market Drivers: Increasing Focus on Precision Medicine Challenges: Unfavorable Drug Prices North America Is Expected To Grow With the Highest CAGR during the Forecast Period Segmentation of CBD API Market-![](\"http:\/\/www.emailwire.com\/files\/pr_images\/mid_thumbs\/1_1726031681_1147234.jpg\" "\\"\\"")
<\/a><\/div>\n
\u0095\tIncreasing demand for cannabidiol for health and wellness
\u0095\tMore focus on precision medicine
\u0095\tIncreasing demand for natural Remedies <\/p>\n
\u0095\tLack of customer awareness
\u0095\tUnfavorable drug prices
\u0095\tDelays in approvals <\/p>\n
\u0095\tEmerging biosimilars market
\u0095\tHigh investments in research
\u0095\tMarket expansions by major players<\/p>\n
\u0095\tRecipharm
\u0095\tMedical Marijuana Inc. (California, U.S.)
\u0095\tCannoidLLC (Colorado, U.S)
\u0095\tIsodiol International Inc. (Vancouver, Canada)
\u0095\tENDOCA (Chicago, U.S.)
\u0095\tFolium Biosciences (Texas, U.S.)
\u0095\tAurora Cannabis Inc. (Edmonton, Canada)
\u0095\tPharmahemp d.o.o (Slovenia, Europe)
\u0095\tElixinol Global (Sydney, Australia)
\u0095\tCV Sciences (California, U.S.)
\u0095\tMedterra CBD (California, U.S.)
\u0095\tAverix Bio, LLC
\u0095\tBiovectra Inc.
\u0095\tVintage Hemp<\/p>\n
\u0095\tIn April 2023, Vantage Hemp Co. submitted a DMF to the FDA for its CBD isolate. The FDA needed the submission (DMF #037784) to make safe and effective CBD products. This engagement established the Company as a transparent and dependable partner to clients and regulators.
\u0095\tIn May 2022, GVB Biopharma was acquired by the 22nd Century Group. This Platform Enabled Rapid Expansion of the Hemp\/Cannabis Franchise. Further, the transaction was immediately accretive, that results in doubling the company’s total revenue, and will add significant commercial scale to the existing hemp\/cannabis franchise.
\u0095\tIn April 2022, Averix Bio and Geocann have established a strategic alliance for distributing pharmaceutical API phytocannabinoid constituents, which were developed utilizing a drug delivery system technology that has been empirically validated in the marketplace.<\/p>\n
One of the main drivers of CBD API market is precision medicine that considers the variability in the environment, lifestyle, and genes of each individual. The approach ensures that the preventive interventions are directed to patients so that benefits are multiplied and cost and complications are minimized. Further, oncology comes out at the top among all therapeutic areas in the area of precision medicine. While conducting clinical trials for such innovative drugs, the objective is to generate pharmacologically effective drug concentrations at the disease site while keeping minimal drug concentrations in the rest of the body.<\/p>\n
Pharmaceutical drug prices have gradually increased globally in the past few years. Although various prominent countries have regulated drug prices. To limit spending on pharmaceuticals, governments of several countries induce price controls. However, revenue of pharmaceutical companies takes a hit because of such regulated drug prices. This, in turn, leads to a reduction in research and development spending and lower new molecular entities (NMEs) being progressed per annum. Since API suppliers’ bargaining power is low, drug product price regulations will directly impact the prices of active pharmaceutical ingredients as well.<\/p>\n
The North America CBD API Market is likely to register a significant revenue share and develop at a rapid CAGR soon. This is because the region has started to liberalize their laws for CBD products in the past few years, leading to increased acceptance amongst locals. The demographics of consumers continue to shift rapidly, and the utility of CBD has become mainstream among several manufacturers such as food, pharma, and cosmetics. The surging demand among different age groups and genders is expected to prompt market growth in this region.<\/p>\n
By Product-
\u0095\tFull spectrum CBD
\u0095\tBroad-spectrum CBD
\u0095\tCBD isolate
\u0095\tWater Dispersible CBD Powder
\u0095\tOthers
By Origin-\t
\u0095\tNatural
\u0095\tSynthetic
By Indication-
\u0095\tAlzheimer’s Disease
\u0095\tAutism
\u0095\tCancer
\u0095\tChronic Pain
\u0095\tEpilepsy
\u0095\tMigraine
\u0095\tMultiple Sclerosis
\u0095\tSchizophrenia
\u0095\tOthers
By End User-
\u0095\tPharmaceutical Industry
\u0095\tUniversity and Research Institutes
\u0095\tOthers
By Region-
North America-
\u0095\tThe US
\u0095\tCanada
\u0095\tMexico
Europe-
\u0095\tGermany
\u0095\tThe UK
\u0095\tFrance
\u0095\tItaly
\u0095\tSpain
\u0095\tRest of Europe
Asia-Pacific-
\u0095\tChina
\u0095\tJapan
\u0095\tIndia
\u0095\tSouth Korea
\u0095\tSouth East Asia
\u0095\tRest of Asia Pacific
Latin America-
\u0095\tBrazil
\u0095\tArgentina
\u0095\tRest of Latin America
Middle East & Africa-
\u0095\tGCC Countries
\u0095\tSouth Africa
\u0095\tRest of Middle East and Africa<\/p>\n